Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Turn Therapeutics Inc ( (TTRX) ) has issued an announcement.
On February 9, 2026, Turn Therapeutics Inc. announced that Chief Executive Officer Brad Burnam would present at the virtual 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026, and at the in-person 46th Annual TD Cowen Healthcare Conference in Boston on March 2, 2026. During these appearances, the company planned to update investors on the status of its Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis and to hold one-on-one meetings with institutional investors.
The company also posted an updated investor presentation to its website on February 9, 2026, underscoring its efforts to increase visibility around its dermatology pipeline and clinical progress. These conference presentations and outreach activities signaled a push to engage the capital markets and healthcare investors at a pivotal stage for GX-03, potentially influencing perceptions of Turn Therapeutics’ growth prospects in the competitive inflammatory and immunology space.
The most recent analyst rating on (TTRX) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
Spark’s Take on TTRX Stock
According to Spark, TipRanks’ AI Analyst, TTRX is a Neutral.
Overall score is held down primarily by weak financial performance (no revenue, ongoing cash burn, and negative equity indicating financing risk). Technicals are a notable offset with bullish momentum (price above key moving averages and positive MACD). Valuation remains a headwind due to negative earnings and no dividend support.
To see Spark’s full report on TTRX stock, click here.
More about Turn Therapeutics Inc
Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision therapies that target the underlying causes of inflammatory diseases with high unmet needs. Its lead investigational product, GX-03, is a first-in-class, non-systemic topical inhibitor in late-stage development for treating moderate-to-severe atopic dermatitis and potentially other inflammatory dermatological conditions.
The company operates in the dermatology segment of the biopharmaceutical industry, concentrating on targeted inflammatory and immunology therapies. By aiming to modulate key inflammatory pathways rather than merely addressing symptoms, Turn Therapeutics positions itself within a growing market for innovative, mechanism-based treatments for chronic skin disorders.
Average Trading Volume: 71,805
Current Market Cap: $113.4M
For detailed information about TTRX stock, go to TipRanks’ Stock Analysis page.